Currently out of the existing stock ratings of Danielle Brill, 167 are a BUY (81.07%), 34 are a HOLD (16.5%), 5 are a SELL (2.43%).

Danielle Brill

Work Performance Price Targets & Ratings Chart

Analyst Danielle Brill, currently employed at TRUIST, carries an average stock price target met ratio of 56.91% that have a potential upside of 38.97% achieved within 219 days. Previously, Danielle Brill worked at RAYMOND JAMES.

Danielle Brill’s has documented 389 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on HRMY, Harmony Biosciences Holdings at 08-Jan-2026.

Wall Street Analyst Danielle Brill

Analyst best performing recommendations are on AGIO (AGIOS PHARM).
The best stock recommendation documented was for XLRN (ACCELERON PHARMA) at 1/8/2020. The price target of $73 was fulfilled within 20 days with a profit of $19.46 (36.35%) receiving and performance score of 18.17.

Average potential price target upside

of $108.39 (27.99%) on ARGX (ARGENX NV ADR).
of $35.88 (34.3%) on NBIX (NEUROCRINE BIOSCIENCES).
of $32.88 (54.79%) on XLRN (ACCELERON PHARMA).

ACAD ACADIA Pharmaceuticals AGIO Agios Pharm ARGX argenx NV ADR FGEN FibroGen GBT Global Blood Therapeutics IMVT Immunovant PASG Passage Bio PTCT PTC Therapeutics SAGE Sage Therapeutic SRPT Sarepta Therapeutics XLRN Acceleron Pharma HRMY Harmony Biosciences Holdings NBIX Neurocrine Biosciences QURE Uniqure NV MOR MorphoSys AG ADR ZGNX Zogenix MNTA Momenta Pharmaceuticals ALKS Alkermes Plc XENE Xenon Pharmaceuticals ALDR Alder BioPharmaceuticals GLYC GlycoMimetics BIIB Biogen VRTX Vertex Pharmaceuticals IRON Disc Medicine GWPH GW Pharmaceuticals plc KROS Keros Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ashwani Verma (UBS)